Cassava Sciences conceded Tuesday that only a relative handful of patients with Alzheimer’s have been enrolled in its late-stage clinical trials — a sign that ongoing investigations over the credibility of its experimental drug simufilam have made physicians and patients wary.
On a company-sponsored webcast, Cassava CEO Remi Barbier said 60 patients have begun treatment across its two Phase 3 clinical trials. The studies, which randomize patients to receive either simufilam or a placebo, have been expected to enroll 1,750 patients.
The studies opened in September and November of last year, respectively, so in roughly six months, Cassava has only managed to recruit 3% of the patients it needs to complete the Phase 3 program.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
